Latest Breaking News On - Positron emissions tomography - Page 1 : comparemela.com

Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)

Preclinical studies show uTREAT® effective in treating non-small cell lung cancer Data follows recent announcement of positive preclinical results within glioblastoma and supports hypothesis.

Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

/PRNewswire/ Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) announces today that the previously announced results from the.

Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WM

COPENHAGEN, Denmark, Sept. 14, 2023 /PRNewswire/ Curasight A/S ("Curasight" or the "Company" - TICKER:.

Curasight: Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight to present at HC Andersen Capital and Økonomisk Ugebrev

Copenhagen, Denmark, 26 May 2023 - Curasight A/S hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company s Interim Report Q1 2023 at HC. | May 26, 2023